Slide 1 M PHARM SEMINAR ON POST MARKETING SURVILLANCE SIKSHAâOâANUSANDHAN UNIVERSITY BHUBANESWAR NAME- GAYATREE UTTARKABAT M PHARM 2nd SEMESTER REG. NO- 1361655001 DATE-2.4.2014…

© Copyright Maitems Analytics India Pvt. Ltd. 2014 Adverse Event Analysis Presented at 2nd International Conference on Business Analytic and Intelligence (ICBAI) Senthil…

Rare Pulmonary Diseases in Systemic JIA Yukiko Kimura, MD Professor of Pediatrics Joseph M Sanzari Children’s Hospital Hackensack University Medical Center Chair Elect…

1. Different Approaches to Spontaneous Reporting:A New Business ModelHow a collaboration between Partners Healthcare, CRIX, Int’l., FDA, CDISC, Pfizer and others is trying…

Slide 1Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Post Market Surveillance KNH/UON Pharmacy Symposium Optimizing Medicine use to Improve Patient Outcome…

Slide 1 Joint meeting of Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees May 6, 2008 Review of Fentora® and Actiq® Adverse Events…

Slide 1 Pharmacoepidemiology: Past, present and future Kathleen Bennett, PhD Department of Pharmacology & Therapeutics, Trinity College Dublin [email protected] 3 rd Sept…

Slide 1 Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 1 Oct 19, 2010 Zhaohui (John) Cai, MD, PhD Director, Biomedical Informatics AstraZeneca PRISM…

Slide 1 1 Module 4 Slide 2 2 History of Good Clinical Practice Regulations Barbara Novak Slide 3 3 BAN/CDR US Food and Drug Law Chronology 1848Congress banned importation…

Spontaneous reporting systems and pharmacovigilance - WHO programme perspective SALUS why is it important? Tomas Bergvall, MSc Uppsala Monitoring Centre WHO Collaborating…